Tarlatamab demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial in lung cancer.
According to GlobalData, US biotech major Amgen’s (Nasdaq: AMGN) bispecific T-cell engager (BiTE) may become a promising lifeline for small cell lung cancer (SCLC) patients - who comprise 15% of 15% of lung tumor patients - and is forecast to achieve peak sales of $788 million by 2029.
Verona Morina, oncology and hematology analyst at the data and analytics provider, said: “The most recent results displayed by tarlatamab may reignite interest in the delta-like ligand 3 (DLL3) antigen present on tumor cells, a target that suffered a setback when AbbVie (NYSE: ABBV) terminated Rova-T, an anti-DLL3 antibody-drug conjugate in 2019, due to its Phase III failure in the treatment of SCLC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze